Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Idenix Pharmaceuticals (UNKNOWN: IDIX.DL ) received more bad news today after reporting that the FDA will require more preclinical data before it can proceed with clinical trials for its experimental hepatitis C drug IDX20963. In the following video, health-care analyst Max Macaluso discusses what this news means in the context of Idenix's previous drug development problems.
Taking a break from the volatile biotech sector? Looking for ways to diversify into dividend-paying stocks? The Motley Fool's special report "Secure Your Future With 9 Rock-Solid Dividend Stocks" is a great way to kick-start your search. Just click here to get your free copy today.